Recently, Murphy and colleagues [1] reported findings from a clinical trial designed to evaluate the effect of home noninvasive ventilation (NIV) with oxygen on time to readmission or death in patients with persistent hypercapnia after an acute chronic obstructive pulmonary disease (COPD) exacerbation. The authors concluded that the addition of home NIV to home oxygen therapy may improve outcomes in patients with severe COPD and persistent hypercapnia following hospital admission.
I would like to make the following observations in relation to the use of NIV in patients with COPD:
1. In COPD patients, NIV may be beneficial when used overnight or during the day at home [2] . When using pressure-targeted ventilation, beginning in the spontaneously triggered mode with a backup rate is recommended. NIV may have some problems related to air pressure and flow, such as gastric insufflation (30 to 40%) and aspiration (5%) [5] . Murphy and colleagues [1] did not report on the side effects of the high pressure strategy. 3. One of the long-term objectives of NIV is to prolong survival [3] . However, Murphy and colleagues [1] reported that 12-month mortality results were not different between the groups (28.1% in the home oxygen plus home NIV group and 32.2% in home oxygen alone group [difference of 4.13%, p = 0.777]) [1] . 4. Finally, the estimated cost of providing a domiciliary NIV service is $3022 in the first year and $1956 in subsequent years [2] , which is a high cost for those with low and lower middle incomes.
Abbreviations COPD: Chronic obstructive pulmonary disease; LES: Lower esophageal sphincter; NIV: Noninvasive ventilation; Pdi: Transdiaphragmatic pressure
